Metabolic Neuropathy Medication

  • Author: Tarakad S Ramachandran, MBBS, FRCP(C), FACP; Chief Editor: Nicholas Lorenzo, MD   more...
 
Updated: Feb 6, 2012
 

Medication Summary

See Medical Care for a full discussion of recent and ongoing studies and symptomatic treatment.

Next

Gastrointestinal agents

Class Summary

These agents increase peristalsis of upper GI tract.

Metoclopramide (Clopra, Reglan, Maxolon)

 

Sensitizes tissue to action of acetylcholine and stimulates motility of upper GI tract; indicated for gastroparesis. In severe gastroparesis, is not absorbed and should be given IV.

Previous
Next

Broad-spectrum antibiotics

Class Summary

Therapy must be comprehensive and cover all likely pathogens in the context of neuropathic enteropathy.

Ampicillin (Omnipen, Marcillin, Polycillin, Principen)

 

Bactericidal activity against susceptible organisms. Alternative to amoxicillin when unable to take medication orally.

Tetracycline (Sumycin)

 

Treats gram-positive and gram-negative organisms as well as mycoplasmal, chlamydial, and rickettsial infections. Inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunit(s).

Metronidazole (Flagyl, Protostat)

 

Imidazole ring-based antibiotic active against various anaerobic bacteria and protozoa. Used in combination with other antimicrobial agents (except for Clostridium difficile enterocolitis).

Previous
Next

Cholinergic agents

Class Summary

These agents increase peristalsis and secretions in the intestine. They also increase contraction and relaxation of the sphincter of the bladder. They may help in treatment of cystopathy.

Bethanechol (Urecholine, Duvoid, Myotonachol)

 

Used for selective stimulation of bladder to produce contraction to initiate micturition and empty bladder. Most useful in patients who have bladder hypocontractility, provided they have functional and coordinated sphincters. Rarely used because of difficulty in timing effect and because of GI stimulation.

Previous
Next

Tricyclic antidepressants

Class Summary

These agents have been shown to be effective in treating painful diabetic neuropathy. They act on CNS, preventing reuptake of norepinephrine and serotonin at synapses involved in pain inhibition. Benefits are unrelated to relief of depression.

Amitriptyline (Elavil)

 

Analgesic for certain types of chronic and neuropathic pain.

Nortriptyline (Aventyl HCl, Pamelor)

 

Has demonstrated effectiveness in treatment of chronic pain. By inhibiting reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, this drug increases synaptic concentration of these neurotransmitters in CNS.

Pharmacodynamic effects such as desensitization of adenyl cyclase and down-regulation of beta-adrenergic receptors and serotonin receptors also appear to play roles in its mechanisms of action.

Previous
Next

Selective serotonin reuptake inhibitors

Class Summary

These agents specifically inhibit presynaptic reuptake of serotonin but not noradrenaline.

Paroxetine (Paxil)

 

Effective in painful diabetic neuropathy.

Previous
Next

Anticonvulsants

Class Summary

Use of certain anti-epileptic drugs, such as the GABA analogue gabapentin, has proven helpful in some cases of neuropathic pain. Thus, a trial of such an agent might provide analgesia for symptomatic neuropathy.

Phenytoin (Dilantin)

 

Blocks sodium channels nonspecifically and therefore reduces neuronal excitability in sensitized C-nociceptors. Has been demonstrated effective in neuropathic pain but suppresses insulin secretion and may precipitate hyperosmolar coma in patients with diabetes.

Carbamazepine (Tegretol)

 

Nonspecific sodium channel blocker that has been effective in treatment of painful diabetic neuropathy; more useful in trigeminal neuralgia.

Gabapentin (Neurontin)

 

Novel anticonvulsant with unknown mechanism of action; believed to antagonize glutamate excitotoxicity. Has demonstrated effectiveness in neuropathic pain, but doses in clinical trials were as high as 3600 mg.

Previous
Next

Analgesics

Class Summary

Recent studies have demonstrated efficacy in different types of neuropathic pain.

Tramadol (Ultram)

 

Analgesic probably acting over both monoaminergic and opioid mechanisms. Monoaminergic effect shared with TCAs. Tolerance and dependence appear to be uncommon.

Previous
Next

Dopamine agonists

Class Summary

In order for a dopamine agonist to offer clinical benefit, it must stimulate D2 receptors. The role of other dopamine receptor subtypes is currently unclear. They inhibit noxious input to spinal cord.

Levodopa (Depar, Larodopa)

 

Has actions over noradrenergic receptors.

Previous
Next

Topical analgesics

Class Summary

Studies have demonstrated efficacy in different types of neuropathic pain. Capsaicin has been shown to have efficacy in treatment of painful diabetic neuropathy and postherpetic neuralgia.

Capsaicin (Dolorac, Zostrix)

 

Derived from chili peppers; depletes substance P from sensory nerves, causing chemodenervation. Has demonstrated effectiveness in several studies of diabetic neuropathic pain and in other types of neuropathic pain.

Previous
Next

Selective serotonin and norepinephrine reuptake inhibitors (SSNRI)

Class Summary

SSNRIs have antidepressant and central pain inhibitory actions.

Duloxetine hydrochloride (Cymbalta)

 

The efficacy of duloxetine in the treatment of neuropathic pain associated with diabetic peripheral neuropathy was established in 2 large, randomized, placebo-controlled trials in adult patients. These studies led to duloxetine becoming the first FDA-approved agent for the treatment of diabetic neuropathic pain. Action is believed to involve inhibition of central pain mechanisms at the recommended dose of 60 mg/d PO.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Tarakad S Ramachandran, MBBS, FRCP(C), FACP  Professor of Neurology, Clinical Professor of Medicine, Clinical Professor of Family Medicine, Clinical Professor of Neurosurgery, State University of New York Upstate Medical University; Chair, Department of Neurology, Crouse Irving Memorial Hospital

Tarakad S Ramachandran, MBBS, FRCP(C), FACP is a member of the following medical societies: American Academy of Neurology, American Academy of Pain Medicine, American College of Forensic Examiners, American College of International Physicians, American College of Managed Care Medicine, American College of Physicians, American Heart Association, American Stroke Association, Royal College of Physicians, Royal College of Physicians and Surgeons of Canada, Royal College of Surgeons of England, and Royal Society of Medicine

Disclosure: Abbott Labs None None; Teva Marion None None; Boeringer-Ingelheim Honoraria Speaking and teaching

Specialty Editor Board

Milind J Kothari, DO  Professor and Vice-Chair, Department of Neurology, Pennsylvania State University College of Medicine; Consulting Staff, Department of Neurology, Penn State Milton S Hershey Medical Center

Milind J Kothari, DO is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Neurological Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Glenn Lopate, MD  Associate Professor, Department of Neurology, Division of Neuromuscular Diseases, Washington University School of Medicine; Director of Neurology Clinic, St Louis ConnectCare; Consulting Staff, Department of Neurology, Barnes-Jewish Hospital

Glenn Lopate, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and Phi Beta Kappa

Disclosure: Baxter Grant/research funds Other; Amgen Grant/research funds None

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Chief Editor

Nicholas Lorenzo, MD  Consulting Staff, Neurology Specialists and Consultants

Nicholas Lorenzo, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, and American College of Physician Executives

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors, Fernando Dangond, MD, and Luis Carlos Sanin, MD, to the development and writing of this article.

References
  1. Tamborlane WV, Ahern J. Implications and results of the Diabetes Control and Complications Trial. Pediatr Clin North Am. Apr 1997;44(2):285-300. [Medline].

  2. Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep. Aug 2010;10(4):276-82. [Medline].

  3. Greene DA, Stevens MJ, Feldman EL. Diabetic neuropathy: scope of the syndrome. Am J Med. Aug 30 1999;107(2B):2S-8S. [Medline].

  4. Voulgari C, Psallas M, Kokkinos A, Argiana V, Katsilambros N, Tentolouris N. The association between cardiac autonomic neuropathy with metabolic and other factors in subjects with type 1 and type 2 diabetes. J Diabetes Complications. May-Jun 2011;25(3):159-67. [Medline].

  5. Dyck PJ, Norell JE, Dyck PJ. Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy. Neurology. Dec 10 1999;53(9):2113-21. [Medline].

  6. Harati Y. Frequently asked questions about diabetic peripheral neuropathies. Neurol Clin. Aug 1992;10(3):783-807. [Medline].

  7. Pirart J. [Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973 (3rd and last part) (author's transl)]. Diabete Metab. Dec 1977;3(4):245-56. [Medline].

  8. Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med. Aug 30 1999;107(2B):9S-16S. [Medline].

  9. Chalk CH. Acquired peripheral neuropathy. Neurol Clin. Aug 1997;15(3):501-28. [Medline].

  10. Dick PJ, Thomas PK, eds. Peripheral Neuropathy. 3rd ed. Philadelphia: WB Saunders Co; 1993.

  11. Comi G, Corbo M. Metabolic neuropathies. Curr Opin Neurol. Oct 1998;11(5):523-9. [Medline].

  12. Thomas PK, Tomlinson DR. Diabetic and hypoglycemic neuropathy. In: Dick PJ, Thomas PK, eds. Peripheral Neuropathy. Philadelphia: WB Saunders Co; 1993:1221.

  13. Apfel SC. Neurotrophic factors in the therapy of diabetic neuropathy. Am J Med. Aug 30 1999;107(2B):34S-42S. [Medline].

  14. Misiunas A, Niepomniszcze H, Ravera B, et al. Peripheral neuropathy in subclinical hypothyroidism. Thyroid. Aug 1995;5(4):283-6. [Medline].

  15. Kyle RA. Monoclonal proteins in neuropathy. Neurol Clin. Aug 1992;10(3):713-34. [Medline].

  16. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. Mar 9 2006;354(10):1021-30. [Medline].

  17. Simmons DN, Lisle DA, Linklater JM. Imaging of Peripheral Nerve Lesions in the Lower Limb. Techniques in Foot & Ankle Surgery. 2008/12;7(4):224-237.

  18. Lisle DA, Johnstone SA. Usefulness of muscle denervation as an MRI sign of peripheral nerve pathology. Australas Radiol. Dec 2007;51(6):516-26. [Medline].

  19. Krishnan AV, Lin CS, Park SB, Kiernan MC. Assessment of nerve excitability in toxic and metabolic neuropathies. J Peripher Nerv Syst. Mar 2008;13(1):7-26. [Medline].

  20. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. Dec 1999;83(3):389-400. [Medline].

  21. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. Jul 2008;31(7):1448-54. [Medline].

  22. Azoulay D, Samuel D, Castaing D, et al. Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg. Dec 1999;189(6):584-93. [Medline].

  23. Kaminski HJ, Ruff RL. Neurologic complications of endocrine diseases. Neurol Clin. Aug 1989;7(3):489-508. [Medline].

  24. Burn DJ, Bates D. Neurology and the kidney. J Neurol Neurosurg Psychiatry. Dec 1998;65(6):810-21. [Medline].

  25. Lagueny A. [Metabolic and nutritional neuropathies]. Rev Prat. Apr 1 2000;50(7):731-5. [Medline].

  26. Parry GJ. Management of diabetic neuropathy. Am J Med. Aug 30 1999;107(2B):27S-33S. [Medline].

Previous
Next
 
Table 1. Symptoms and Signs of Peripheral Neuropathy*
Small-Fiber SensoryLarge-Fiber SensoryAutonomic
Burning painLoss of vibrationHeart rate changes
Cutaneous allodyniaProprioception lossPostural blood pressure change
ParesthesiasLoss of reflexesAbnormal sweating
Lancinating painSlowed NCVsGastroparesis
Loss pain/temperatureSensory ataxiaImpotence
Foot ulcersWeaknessAbnormal ejaculation
Visceral pain loss
* Modified from Apfel, 1999.[13]
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.